The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 study of atezolizumab with carboplatin plus pemetrexed followed by maintenance atezolizumab with pemetrexed for elderly patients with advanced non-squamous non-small cell lung cancer: CJLSG1902.
 
Hidetoshi Itani
Speakers' Bureau - Chugai Pharma; Lilly Japan
Research Funding - Chugai Pharma (Inst)
 
Akiko Kada
No Relationships to Disclose
 
Kazuma Kishi
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim
 
Kazushige Wakuda
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Daiichi Sankyo/UCB Japan (Inst); MSD (Inst)
 
Ryo Morita
No Relationships to Disclose
 
Kosuke Takahashi
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
 
Takeshi Tsuda
Honoraria - AstraZeneca; Chugai Pharma; Merck
Research Funding - Chugai Pharma; MSD K.K.
 
Naoki Furuya
No Relationships to Disclose
 
Jun Sugisaka
Honoraria - AstraZeneca; Kyowa Kirin International
 
Yuta Yamanaka
No Relationships to Disclose
 
Shinji Nakamichi
No Relationships to Disclose
 
Toshiyuki Kozuki
Honoraria - Abbvie; Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Merck; MSD; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Sawai Pharmaceutical Co; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo/UCB Japan; Ono Pharmaceutical; Pfizer
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dizal Pharma (Inst); Eisai (Inst); Gilead Sciences (Inst); Kyowa-Hakko Kirin (Inst); Merck (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)
 
Toshihiko Yokoyama
No Relationships to Disclose
 
Akiko Saito
No Relationships to Disclose
 
Hideo Saka
Honoraria - AstraZeneca; Chugai Pharma; Kaneka Corporation; Taiho Pharmaceutical
Research Funding - Janssen (Inst)
 
Masashi Kondo
No Relationships to Disclose